This statement comes at a time when the race for Covid-19 vaccine is heating up across the world. Though most vaccine makers have received ...

The US is the largest donor to the WHO with a contribution of $400 million in 2018-19. WHO India’s country budget was reported to be a litt...

The recommendations come as four Indian drug companies, Cipla, Hetero, Mylan and Jubilant, gear up to get an approval for the drug in the t...

The Indian company had submitted its application for manufacturing the Covid-19 drug to the Drug Controller General of India (DCGI) last we...

In India, the drug sold under the brand name Actemra, is approved for the use in autoimmune disease such as rheumatoid arthritis and for si...

MDR TB is on the rise in India which, together with China and Russia, accounts for over half of these cases worldwide, according to a recen...

The licences and approvals can be made perpetual provided they are not cancelled or suspended by the licencing authority, according to the ...

MSF filed declarations at the Delhi patent office to point out that Pfizer's 13-valent pneumococcal conjugate vaccine (PCV13) was obvious a...

In a writ petition filed at the Supreme Court of India, Thakur has sued the health ministry , Central Drugs Standard Control Organisation .

The government’s move to withdraw customs duty exemption on imports of 76 life-saving drugs will have minimal impact on patients, according...

The government's healthcare outlay is stagnant at around Rs 33,000 crore and has not translated to the increase from 1.2% of GDP to 2-2.5%

Indian drugmakers are also concerned about a shift in India’s position on IPR, which they say is being keenly watched by many developing co...

The reason for the shortage is not a paucity of funds but delay by the NACO in placing tenders for procurement, experts said.

Drugmakers are worried that the India-EU FTA, which is in the works, may contain a provision that could imperil local industry.

The IPAB revoked Roche's patent for Pegasys on grounds that the process of pegylation did not enhance the efficacy of the drug.

India has rejected American drugmaker Bristol-Myers Squibb's (BMS) patent application for one of its HIV drugs, allowing local drugmakers t...

Govt’s plan to boost research and development using public funds has raised sharp reactions from public interest groups on the commercial r...